title: Biologic therapies targeting eosinophils: current status and future prospects.
abstract: The recent explosion in the number of biologic therapies in clinical development for the treatment of eosinophilic disorders is unprecedented. As these agents become available for clinical use, the selection of the most appropriate agent for a given patient will become increasingly complicated. The aims of this review were 2-fold: (1) to present the lessons learned from clinical trials using the first generation of eosinophil-targeted biologics (anti-IL-5 antibodies) and (2) to discuss the advantages and potential limitations of currently available and novel targeted therapies to treat eosinophilic disorders.
authors.affiliation: Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda.
authors.forename: Fanny
authors.initials: F
authors.lastname: Legrand
authors.affiliation: Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda. Electronic address: aklion@nih.gov.
authors.forename: Amy D
authors.initials: AD
authors.lastname: Klion
mesh_terms: D000818:Animals; D001691:Biological Therapy; D004804:Eosinophils / Q000276:immunology*; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy* / Q000276:immunology; D015848:Interleukin-5 / Q000276:immunology
chemical_list: D015848:Interleukin-5
keywords: Asthma; Benralizumab; Eosinophilic gastrointestinal disorders; Hypereosinophilic syndrome; Mepolizumab; Reslizumab; mAb